CLNN News and Press, Clene Inc. From 01/08/24

Long-term CNM-Au8 treatment demonstrated improvement of vision as measured by low contrast visual acuity (LCLA), an assessment of visual function in people living with multiple sclerosis (MS), through 35 months from randomization, p<0.0001 Long-term CNM-Au8 treatment demonstrated improveme...

Common knowledge coupled with numerous polls on lifestyle and longevity indicate that exercise generally contributes to longer lives . Physicians consistently encourage their patients to exercise regularly, and many experts contend that the modern sedentary lifestyle has significantly contribute...

2023-12-21 09:06:53 ET More on Clene Clene gains after $45M federal grant to study lead asset in ALS Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene For further details see: Clene dow...

SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal fu...

CNM-Au8 30mg treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels at 76 weeks relative to placebo (18 months from randomization, p=0.023) 60% decreased risk of long-term all-cause mortality (>18 months, p=0.0167) in participants originally rand...

Clene, a late clinical-stage biopharmaceutical company, creates clean-surfaced, catalytically active nanocrystals that directly modulate biological systems, including the central nervous system, by improving mitochondrial health The company’s lead investigational candidate, CNM-Au8(R), i...

Clene (NASDAQ: CLNN) , a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease and multiple sclerosis (...

Journal of Nanobiotechnology publication describes results from the successful Phase 2 REPAIR clinical studies that measured changes in brain energy metabolites in multiple sclerosis and Parkinson’s disease with CNM-Au8 ® treatment Data show significant increase in brain N...

A team of researchers from Italy’s Hospital Casa Solleivo della Sofferenza, the University of Milan Bicocca and the University of Cambridge have discovered that stem cell therapy may be effective at slowing the progression of cognitive decline in patients with multiple sclerosis (MS). MS...

Clene (NASDAQ: CLNN) , together with its wholly owned subsidiary Clene Nanomedicine Inc., recently provided operating highlights for its amyotrophic lateral sclerosis (“ALS”) clinical program. “In August, Clene reported a 24-month long-term data cut from the open-label extens...